<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117423</article-id><article-id pub-id-type="publisher-id">ACM-43683</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_93746622.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肝硬化并PVT的治疗
  Treatment of Liver Cirrhosis with PVT
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>雷</surname><given-names>芯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>2920</fpage><lpage>2925</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  门静脉血栓(PVT)是肝硬化的常见并发症之一(在肝硬化患者中的发生率为0.6%~26%)，是指发生于门静脉主干、肠系膜上静脉、肠系膜下静脉或脾静脉的血栓，PVT起病较为隐匿，可导致不良结局，包括消化道出血、肝功能持续恶化、肠道坏死等。PVT的早期诊断及治疗可提高患者的生存率及生活质量，但目前暂无有效指标可提示患者早期PVT的发生，PVT的治疗国内外也暂无统一的指南。目前大多数研究表明肝硬化PVT患者早期抗凝治疗可显著提高门静脉血栓再通率。虽然PVT早期抗凝已达成共识，但具体的抗凝时机、抗凝药物的选择目前还无统一共识。本文就近年来PVT诊断及治疗方面取得的进展进行简要综述，以期为PVT患者的临床诊断及治疗提供理论参考。
   Portal vein thrombosis (PVT) is one of the common complications of cirrhosis (incidence 0.6%~26% in cirrhotic patients) and refers to thrombi that occur in the main portal vein trunk, superior mesenteric vein, inferior mesenteric vein, or splenic vein, and PVT has a more insidious onset and can lead to adverse outcomes, including gastrointestinal bleeding, persistent deterioration of liver function, and intestinal necrosis, etc. The early diagnosis and treatment of PVT can improve the survival rate and quality of life of patients, but there are currently no effective indicators to suggest the occurrence of early PVT in patients, and the treatment of PVT has no uniform guidelines at home and abroad. Most of the current studies have shown that early anticoagulation in cirrhotic patients with PVT significantly increases the rate of portal vein thrombus recanalization. Although there is a consensus on early anticoagulation in PVT, there is currently no consensus on the specific timing of anticoagulation, the choice of anticoagulant. In this review, we briefly summarize the recent progress in the diagnosis and treatment of PVT, with the aim of providing a theoretical reference for the clinical diagnosis and treatment of patients with PVT.
 
</p></abstract><kwd-group><kwd>门静脉血栓，肝硬化，诊断，抗凝，治疗, Portal Vein Thrombosis</kwd><kwd> Cirrhosis of Liver</kwd><kwd> Diagnosis</kwd><kwd> Anticoagulation</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>门静脉血栓(PVT)是肝硬化的常见并发症之一(在肝硬化患者中的发生率为0.6%~26%)，是指发生于门静脉主干、肠系膜上静脉、肠系膜下静脉或脾静脉的血栓，PVT起病较为隐匿，可导致不良结局，包括消化道出血、肝功能持续恶化、肠道坏死等。PVT的早期诊断及治疗可提高患者的生存率及生活质量，但目前暂无有效指标可提示患者早期PVT的发生，PVT的治疗国内外也暂无统一的指南。目前大多数研究表明肝硬化PVT患者早期抗凝治疗可显著提高门静脉血栓再通率。虽然PVT早期抗凝已达成共识，但具体的抗凝时机、抗凝药物的选择目前还无统一共识。本文就近年来PVT诊断及治疗方面取得的进展进行简要综述，以期为PVT患者的临床诊断及治疗提供理论参考。</p></sec><sec id="s2"><title>关键词</title><p>门静脉血栓，肝硬化，诊断，抗凝，治疗</p></sec><sec id="s3"><title>Treatment of Liver Cirrhosis with PVT<sup> </sup></title><p>Xin Lei, Peng Ma</p><p>Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/4-1572359x4_hanspub.png" /></p><p>Received: Jun. 1<sup>st</sup>, 2021; accepted: Jun. 22<sup>nd</sup>, 2021; published: Jul. 5<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/4-1572359x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Portal vein thrombosis (PVT) is one of the common complications of cirrhosis (incidence 0.6%~26% in cirrhotic patients) and refers to thrombi that occur in the main portal vein trunk, superior mesenteric vein, inferior mesenteric vein, or splenic vein, and PVT has a more insidious onset and can lead to adverse outcomes, including gastrointestinal bleeding, persistent deterioration of liver function, and intestinal necrosis, etc. The early diagnosis and treatment of PVT can improve the survival rate and quality of life of patients, but there are currently no effective indicators to suggest the occurrence of early PVT in patients, and the treatment of PVT has no uniform guidelines at home and abroad. Most of the current studies have shown that early anticoagulation in cirrhotic patients with PVT significantly increases the rate of portal vein thrombus recanalization. Although there is a consensus on early anticoagulation in PVT, there is currently no consensus on the specific timing of anticoagulation, the choice of anticoagulant. In this review, we briefly summarize the recent progress in the diagnosis and treatment of PVT, with the aim of providing a theoretical reference for the clinical diagnosis and treatment of patients with PVT.</p><p>Keywords:Portal Vein Thrombosis, Cirrhosis of Liver, Diagnosis, Anticoagulation, Treatment</p><disp-formula id="hanspub.43683-formula17"><graphic xlink:href="//html.hanspub.org/file/4-1572359x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1572359x7_hanspub.png" /> <img src="//html.hanspub.org/file/4-1572359x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>门静脉血栓(PVT)是指发生于门静脉主干、肠系膜上静脉、肠系膜下静脉或脾静脉的血栓。可分为急性门静脉血栓和慢性门静脉血栓。肝硬化是PVT发生的重要病因之一，但具体机制暂不明确 [<xref ref-type="bibr" rid="hanspub.43683-ref1">1</xref>]，血流动力学紊乱、血管内皮损伤、血液高凝状态是PVT形成的主要危险因素。在慢性期病人通常表现为静脉曲张出血或门静脉高压等其他临床变现。而在急性门静脉血栓形成临床表现可从无症状到危及生命的肠缺血和梗死的出现。PVT作为肝硬化的并发症在临床上越来越常见。一项荟萃分析表明，与其他病因相比，非酒精性脂肪肝炎引起的肝硬化形成PVT的风险可能更高 [<xref ref-type="bibr" rid="hanspub.43683-ref2">2</xref>]。根据这一研究我们可以看出PVT患者在逐渐增加。肝硬化合并PVT患者逐渐增多，且易导致严重后果，因此肝硬化并发门静脉血栓的早期诊断治疗可以改善患者预后及生活质量。早些年认为肝硬化后患者肝功能严重受损，凝血因子合成障碍，外源性凝血途径及内源性凝血途径受到抑制，食管胃底静脉曲张出血风险增加，即使患者肝硬化合并PVT也暂不考虑抗凝治疗，但近年来越来越多的研究表明抗凝治疗效果好且不会增加出血风险，可用于肝硬化合并PVT的治疗，TIPS、溶栓、手术治疗等治疗手段也可作为治疗的选择。虽然抗凝治疗已经逐渐被大众所认同，但抗凝时机及抗凝药物尚未取得共识 [<xref ref-type="bibr" rid="hanspub.43683-ref3">3</xref>]。</p></sec><sec id="s6"><title>2. 肝硬化并PVT患者的诊断</title><p>肝硬化合并PVT患者通常有慢性肝病史和典型的影像学表现。首选的影像学检查为多普勒超声，增强CT及MRI检查有助于明确诊断。超声因其无创、经济、敏感性高为PVT筛查的一线方法。对于完全性PVT，灵敏度约为90%；对于部分性PVT，灵敏度约为50%。急性PVT形成时，门静脉直径通常 &gt; 13 mm，并且不受呼吸运动的影响。然而超声对一些附壁的小血栓检出率较低，且易受到检查者及患者个体差异的影响，有一定局限性。CT及MRI检查，尤其是门静脉重建，可用于进一步确诊PVT，其对肠系膜静脉血栓和脾静脉血栓的诊断更具优势。新发PVT在CT和MRI扫描下可表现为门静脉管腔内高密度影；门静脉海绵样变性在CT增强和MRI扫描下表现为阻塞的门静脉周围有诸多细小、迂曲的侧支血管。对于影像学表现有PVT的患者但肝硬化诊断证据不足的可考虑肝穿刺活检结合生化指标诊断肝硬化并PVT。DSA是临床诊断PVT的金标准，但随着上述一系列非侵入性成像技术的普及，目前已经很少开展，一般只在无条件行超声、CT、MRI检查时实施 [<xref ref-type="bibr" rid="hanspub.43683-ref4">4</xref>]。</p><sec id="s6_1"><title>2.1. 肝硬化PVT的分期</title><p>肝硬化PVT根据血栓形成过程可以分为急性和慢性PVT，确定PVT患者的分期对采取具体的治疗方案极其重要。急性PVT是指一个月内形成的门静脉主干极其分支的血栓 [<xref ref-type="bibr" rid="hanspub.43683-ref5">5</xref>]，经常会引起相关器官的功能障碍，最常表现为腹痛，其次表现为脾大、腹水形成、呕吐、发热、腹泻、恶心等症状 [<xref ref-type="bibr" rid="hanspub.43683-ref6">6</xref>]。如急性血栓形成导致曲张的侧支循环血管破裂出血则有可能会引起低血压休克及肝性脑病等危及生命的表现。慢性PVT则表现较为隐匿，一般无临床症状，多在体检或肝硬化随诊过程中影像结果回报，如入慢性血栓持续进展，可加重门脉高压症状，例如肝功能缓慢恶化，食管胃底静脉曲张加重甚至伴有出血，腹水形成并缓慢增加。另外广泛的慢性PVT阻塞还可引起继发门静脉海绵样变。慢性门静脉血栓形成时侧支循环血管压力增加，血管扩张压迫胆道，引起慢性的胆囊炎及胆汁淤积及胆结石形成，消化功能减退。</p></sec><sec id="s6_2"><title>2.2. 肝硬化PVT的严重程度</title><p>目前，我国学者提倡将肝硬化PVT的严重程度分为附壁、部分性、阻塞性和条索化，这对于临床上指导肝硬化并PVT患者的治疗有着重要意义。具体来说，附壁PVT是指新形成的血栓占据了门静脉管腔的50%以下；阻塞性PVT是指血栓完全占据了管腔 [<xref ref-type="bibr" rid="hanspub.43683-ref6">6</xref>]；部分性PVT是指血栓占比介于附壁和阻塞性之间；条索化PVT是指血栓长期阻塞门静脉而发生机化，影像学检查无法探明门静脉管腔 [<xref ref-type="bibr" rid="hanspub.43683-ref7">7</xref>]。</p></sec><sec id="s6_3"><title>2.3. 肝硬化PVT的转归评判</title><p>评估肝硬化PVT患者治疗效果的有效指标为门静脉血栓的动态变化，根据PVT患者的转归评判可及时调整治疗方案以便于达到更好的治疗效果。肝硬化PVT的转归可分为新发、部分再通、完全再通、进展、稳定和复发。新发是指既往影像学检查无血栓，本次为首次诊断为血栓。部分再通是指血栓严重程度较之前降低但还未达到完全再通。完全再通是指经过治疗后患者血栓完全消失。进展是指经过治疗后患者血栓较之前有所加重。稳定是指血栓经过治疗后较之前无明显变化。复发是指经过治疗后和患者血栓完全消失后再次出现新的血栓 [<xref ref-type="bibr" rid="hanspub.43683-ref8">8</xref>]。</p></sec></sec><sec id="s7"><title>3. 肝硬化并PVT患者的治疗</title><p>肝硬化并PVT患者的治疗主要包括抗凝治疗、TIPS及介入治疗。另外有一部分PVT患者无需治疗即可出现自发性的血栓再通，但暂无有效方法可识别此类患者。PVT患者的转归很大程度上取决于最早治疗时间，越早给予治疗则患者的预后更好，血栓再通率更高，但目前尚未明确启动抗凝的最佳时机。对于急性肝硬化PVT患者应尽早启动抗凝治疗，如经过抗凝治疗后患者出现血栓的进展并出现肠缺血及肠坏死表现应即使行外科手术治疗。对于抗凝效果不良好或有抗凝的禁忌症、急性PVT合并食管胃底静脉曲张破裂出血的患者可考虑使用TIPS治疗 [<xref ref-type="bibr" rid="hanspub.43683-ref9">9</xref>]。</p><sec id="s7_1"><title>3.1. 抗凝治疗</title><p>1) 传统意义上认为肝硬化患者肝功能减退，凝血因子合成障碍，肝硬化合并PVT患者门静脉压力增高导致脾静脉淤血引发脾功能亢进，血小板破坏增多，门静脉压力增加导致侧支循环增加，食管胃底静脉曲张，患者出血风险明显增加，故一般不给予抗凝治疗。根据两项Meta分析研究表明，抗凝治疗后肝硬化合并PVT患者门静脉再通率为66%~71%，门静脉完全再通率为41.5%~53%，血栓进展率为5.7%~9.0% [<xref ref-type="bibr" rid="hanspub.43683-ref10">10</xref>]，此研究表明肝硬化并PVT的患者抗凝治疗可明显增加患者血栓再通率，但两者之间出血风险无明显差异。另外有研究表明抗凝治疗可延长肝硬化PVT患者的生存时间。但目前国内外研究均存在样本量小、偏差较大、选择样本患者是存在偏差无法排除其他非肝硬化导致的PVT患者或血凝正常的肝硬化PVT患者，因此我们在选择抗凝治疗时需要对患者情况进行整体全面的评估，对于出血风险较高的患者可选用非选择性β-受体阻断药或在内经下行食管胃底静脉破裂出血的一级或二级预防 [<xref ref-type="bibr" rid="hanspub.43683-ref11">11</xref>]。若无抗凝禁忌症的肝硬化并PVT的患者应早期抗凝治疗。</p><p>2) 临床上目前常用的抗凝药物有低分子肝素、华法林及利伐沙班等药物</p><p>① 低分子肝素与普通肝素相比，低分子肝素使用方便，不需要检测APTT时间，可以皮下给药，吸收迅速，较少引起血小板减少性紫癜。分子量的减少会降低肝素的抗IIa的活性，但对抗Xa的影响不大；与普通肝素一样，低分子肝素不能用于有活动性出血、血小板减少性紫癜、近期有颅脑手术或出血史、创伤、心内膜炎和重度高血压患者。肌酐清除率低于30 ml/min者需减半量，低于15 ml/min则禁用。根据一项研究表明低分子肝素对凝血酶和血小板功能影响而导致的出血现象等不良反应减少，可达到利抗血栓的目的 [<xref ref-type="bibr" rid="hanspub.43683-ref12">12</xref>]。</p><p>② 华法林是香豆素类口服抗凝药。其作用机制是竞争性拮抗维生素K的作用，使维素K依赖凝血因子II、VII、IX、X等的合成显著减少，从而延长凝血酶原时间。本品在体内需待已合成的上述凝血因子耗竭后，才能发挥作用，一般使用3~5天后才能起效，需要7~10天才能处于稳态。在使用过程中需要监，测凝血功能，将凝血酶原时间国际化标准比值(INR)控制在2.0~3.0，依据INR调整剂量，小剂量逐步递增直至达标；对于栓塞高危者的一级预防或者血栓栓塞者的二级预防，可使用低分子肝素桥接至INR达标。一些回顾性研究表明口服华法林可显著提高PVT再通率 [<xref ref-type="bibr" rid="hanspub.43683-ref13">13</xref>]。</p><p>③ 利伐沙班是Xa因子的抑制剂，与华法林相比，利伐沙斑剂量相对固定，不需要频繁监测 [<xref ref-type="bibr" rid="hanspub.43683-ref14">14</xref>]，很少与食物或者其他药物相互作用，可提高患者的依存性。利伐沙斑起效快，口服后血浆药物达峰值时间2~4小时；其半衰期也相对较短，在7~4小时；因此，一般不建议低分子肝素桥接 [<xref ref-type="bibr" rid="hanspub.43683-ref15">15</xref>]。在轻度肝功能损害(Child Pugh A级)的肝硬化患者中，利伐沙班药代动力学仅发生轻微变化(平均AUC升高1.2倍)，与健康对照组相近。在中度肝功能损害(Child Pugh B级)的肝硬化患者中，利伐沙班的平均AUC与健康志愿者相比显著升高了2.3倍。非结合AUC升高了2.6倍。与中度肾功能损害患者相似，中度肝功能损害患者的利伐沙班肾脏清除率降低。因此对于肝功能中度和重度患者使用利伐沙班治疗肝硬化PVT需要谨慎 [<xref ref-type="bibr" rid="hanspub.43683-ref16">16</xref>]。</p><p>*AUC：即药–时曲线，即血药浓度–时间曲线，指血药浓度随时间变化的动态过程，以血药浓度为纵坐标，以时间为横坐标绘制的曲线。药–时曲线下面积(AUC)是坐标轴与药–时曲线围成的面积，反应药物进入体循环的相对量 [<xref ref-type="bibr" rid="hanspub.43683-ref16">16</xref>]。</p><p>前些年一些研究表明选择不同的抗凝药物治疗PVT，门静脉血栓再通率有显著统计学差异，低分子肝素和利伐沙班对于PVT患者治疗疗效无统计学差异，但明显优于华法林，且与华法林相比低分子肝素及利伐沙班的出血风险明显降低 [<xref ref-type="bibr" rid="hanspub.43683-ref17">17</xref>]。但最新一项循证医学研究表明，低分子肝素、华法林及利伐沙班对于治疗肝硬化门静脉PVT患者的血栓再通率及出血风险并无统计学差异 [<xref ref-type="bibr" rid="hanspub.43683-ref18">18</xref>]。</p><p>④ 抗凝时机的选择</p><p>肝硬化PVT患者抗凝治疗应该个体化。对于急性症状性PVT患者和已经出现肠系膜血栓形成的患者在排除抗凝禁忌症后尽快实施抗凝治疗，主要禁忌症包括严重血小板减少或者严重的食管胃底静脉曲张及近期大量出血史。对于抗凝治疗后血栓进展、稳定和复发的患者且有出现肠坏死表现的患者应该及时联系外科行手术治疗。对于慢性PVT患者在行抗凝治疗前应充分评估患者出血风险，存在食管胃底静脉曲张破裂出血患者应该在内镜下行曲张血管破裂出血的一级及二级预防，或使用β-受体阻断药后再次充分评估患者整体情况后实施抗凝治疗。</p><p>⑤ 抗凝过程中出血处理</p><p>抗凝过程中如果出现出血，根据患者出血严重程度延缓或者停止使用抗凝药物，及早行血常规、血凝、肝功能及消化内镜检查评估患者严重程度，发生大量出血时及时使用止血药物、输注血小板、血红蛋白及病毒灭活血浆等替代治疗，发生消化道大量出血时可于内镜下行止血治疗 [<xref ref-type="bibr" rid="hanspub.43683-ref19">19</xref>]。</p></sec><sec id="s7_2"><title>3.2. 经颈静脉肝内门体分流术(TIPS)治疗</title><p>对于有抗凝治疗禁忌症的PVT患者或合并有食管胃底静脉曲张破裂性出血内科保守治疗效果不佳，或急性症状性PVT患者合并有食管胃底静脉曲张破裂出血患者可行TIPS治疗 [<xref ref-type="bibr" rid="hanspub.43683-ref20">20</xref>]。但目前来说TIPS操作有一定难度，无法得到普及且TIPS容易加重患者肝性脑病风险，故TIPS治疗暂不推介作为首选治疗方案，目前TIPS治疗仍存在争议。</p></sec></sec><sec id="s8"><title>4. 小结</title><p>随着生活水平及饮食结构的改变，肝硬化发病率有所增加，肝硬化后PVT患者早期抗凝治疗可以改善预后，增加远期生存率。但在抗凝前应系统评估患者出血风险，对于出血风险较高的患者应行预防治疗后抗凝，抗凝期间应密切监测患者凝血系列及其余出血表现。最新研究表明临床常用抗凝药物对于血栓再通率无明显统计学差异，但笔者认为相比于华法林，低分子肝素及利伐沙班出血风险更低。对于不适合抗凝治疗的患者，可谨慎考虑TIPS治疗。</p></sec><sec id="s9"><title>文章引用</title><p>雷 芯,马 鹏. 肝硬化并PVT的治疗Treatment of Liver Cirrhosis with PVT[J]. 临床医学进展, 2021, 11(07): 2920-2925. https://doi.org/10.12677/ACM.2021.117423</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43683-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">吴雯玥, 孔德润. 门静脉血栓诊治的一些新认识[J]. 世界华人消化杂志, 2021, 29(4): 165-173.</mixed-citation></ref><ref id="hanspub.43683-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Stine, J.G., Shah, P.M., Cornella, S.L., et al. (2015) Portal Vein Thrombosis, Mortality and Hepatic Decompensation in Patients with Cirrhosis: A Meta-Analysis. World Journal of Hepatology, 7, 2774-2780.</mixed-citation></ref><ref id="hanspub.43683-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张世鑫. 肝硬化门静脉血栓管理专家共识(2020年, 上海) [J]. 中华医学信息导报, 2020, 35(24): 22.</mixed-citation></ref><ref id="hanspub.43683-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Alzubaidi, S., Patel, I., Saini, A., Knuttinen, G., Naidu, S., Kriegshuaser, S., Albadawi, H. and Oklu, R. (2019) Current Concepts in Portal Vein Thrombosis: Etiology, Clinical Presentation and Management. Abdominal Radiology (NY), 44, 3453-3462. &lt;br&gt;https://doi.org/10.1007/s00261-019-02174-1</mixed-citation></ref><ref id="hanspub.43683-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">李婷, 李俊峰, 毛小荣. 肝硬化门静脉血栓发生的危险因素及治疗进展[J]. 中国实用内科杂志, 2021, 41(2): 159-162.</mixed-citation></ref><ref id="hanspub.43683-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">胡利萍. 肝硬化合并门静脉血栓与FCGR2A、SNAP23相关临床研究[D]: [博士学位论文]. 乌鲁木齐: 新疆医科大学, 2020.</mixed-citation></ref><ref id="hanspub.43683-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tsochatzis, E.A., Bosch, J. and Burroughs, A.K. (2014) Liver Cirrhosis. The Lancet, 383, 1749-1761.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(14)60121-5</mixed-citation></ref><ref id="hanspub.43683-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">张丽, 王海燕, 王艳芳, 吕军宁. Child-Pugh B级肝硬化合并门静脉血栓患者利伐沙班口服抗凝治疗效果观察[J]. 中国药物与临床, 2021, 21(1): 97-99.</mixed-citation></ref><ref id="hanspub.43683-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, T., Sun, X., Zhou, T., Li, Y., Chen, X., Cheng, B. and Gao, Y. (2020) Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial. Clinical and Translational Gastroenterology, 11, e00228. &lt;br&gt;https://doi.org/10.14309/ctg.0000000000000228</mixed-citation></ref><ref id="hanspub.43683-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">韩朝, 吴清明. 肝硬化并门静脉血栓诊疗进展[J]. 医学综述, 2021, 27(1): 131-135.</mixed-citation></ref><ref id="hanspub.43683-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">de Franchis, R. (2015) Expanding Consensus in Portal Hypertension: Report of the Baveno VI Consensus Workshop: Stratifying Risk and Individualizing Care for Portal Hypertension. Journal of Hepatology, 63, 743-752.  
&lt;br&gt;https://doi.org/10.1016/j.jhep.2015.05.022</mixed-citation></ref><ref id="hanspub.43683-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Gertsch, P., Matthews, J., Lerut, J., et al. (1993) Acute Thrombosis of the Splanchnic Veins. The Archives of Surgery, 128, 341-345.</mixed-citation></ref><ref id="hanspub.43683-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Priyanka, P., Kupec, J.T., Krafft, M., Shah, N.A. and Reynolds, G.J. (2018) Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. International Journal of Hepatology, 2018, Article ID: 8432781. &lt;br&gt;https://doi.org/10.1155/2018/8432781</mixed-citation></ref><ref id="hanspub.43683-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mohan, B.P., Aravamudan, V.M., Khan, S.R., Ponnada, S., Asokkumar, R. and Adler, D.G. (2020) Treatment Response and Bleeding Events Associated with Anticoagulant Therapy of Portal Vein Thrombosis in Cirrhotic Patients: Systematic Review and Metaanalysis. Annals of Gastroenterology, 33, 521-527.  
&lt;br&gt;https://doi.org/10.20524/aog.2020.0503</mixed-citation></ref><ref id="hanspub.43683-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Villa, E., Camma, C., Marietta, M., Luongo, M., Critelli, R., Colopi, S., Tata, C., Zecchini, R., Gitto, S., Petta, S., Lei, B., Bernabucci, V., Vukotic, R., De Maria, N., Schepis, F., Karampatou, A., Caporali, C., Simoni, L., Del Buono, M., Zambotto, B., Turola, E., Fornaciari, G., Schianchi, S., Ferrari, A. and Valla, D. (2012) Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients with Advanced Cirrhosis. Gastroenterology, 143, 1253-1260e4.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2012.07.018</mixed-citation></ref><ref id="hanspub.43683-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Naymagon, L., Tremblay, D., Zubizarreta, N., Moshier, E., Troy, K., Schiano, T. and Mascarenhas, J. (2020) The Efficacy and Safety of Direct Oral Anticoagulants in Noncirrhotic Portal Vein Thrombosis. Blood Advances, 4, 655-666.  
&lt;br&gt;https://doi.org/10.1182/bloodadvances.2019001310</mixed-citation></ref><ref id="hanspub.43683-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">European Association for the Study of the Liver (2016) EASL Clinical Practice Guidelines: Vascular Diseases of the Liver. Journal of Hepatology, 64, 179-202. &lt;br&gt;https://doi.org/10.1016/j.jhep.2015.07.040</mixed-citation></ref><ref id="hanspub.43683-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425.</mixed-citation></ref><ref id="hanspub.43683-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Loffredo, L., Pastori, D., Farcomeni, A. and Violi, F. (2017) Effects of Anticoagulants in Patients with Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-Analysis. Gastroenterology, 153, 480-487.e1.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2017.04.042</mixed-citation></ref><ref id="hanspub.43683-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wu, M., Schuster, M. and Tadros, M. (2019) Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants. Journal of Clinical and Translational Hepatology, 7, 154-164.  
&lt;br&gt;https://doi.org/10.14218/JCTH.2018.00057</mixed-citation></ref></ref-list></back></article>